Is Iodine-125 Monotherapy Suitable for the Full Spectrum of Intermediate Risk Prostate Cancer?

W. James Morris,Ross Halperin,Mira Keyes,Tom Pickles,Ingrid Spadinger

Brachytherapy（2018）

引用 0|浏览48

暂无评分

摘要

To analyze the effect of prognostic variables and treatment factors on biochemical progression free survival (b-PFS) using a consecutive cohort of 4150 Iodine-125 low-dose-rate prostate brachytherapy (LDR-PB) monotherapy patients treated in a multi-centre, multi-practitioner setting.

查看译文

关键词

intermediate risk prostate cancer,prostate cancer,monotherapy suitable

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要